Egrifta (Tesamorelin) Pediatric (Under 12) Monitoring

Why Tesamorelin Has No Pediatric Indication

Tesamorelin received FDA approval in November 2010 strictly for reduction of excess abdominal fat in HIV-infected adults with lipodystrophy [1]. The approval was based on two Phase III trials enrolling adults aged 18 to 65. Theratechnologies has not submitted a supplemental New Drug Application for any pediatric population, and the FDA has not issued a Written Request or Pediatric Study Decision requiring pediatric trials for this compound.

The Pediatric Research Equity Act (PREA) can mandate pediatric studies for new molecular entities, but tesamorelin received a waiver. The FDA label states: "Safety and effectiveness in pediatric patients have not been established" [2]. This single sentence carries regulatory weight. It means no dose, no schedule, and no monitoring protocol has been validated in children.

HIV-associated lipodystrophy does occur in children receiving antiretroviral therapy (ART). A cross-sectional analysis of the Pediatric HIV/AIDS Cohort Study (PHACS) found that 33% of perinatally HIV-infected youth had evidence of fat redistribution by age 13 [3]. The condition exists. The treatment evidence does not.

Pharmacologic Rationale for Heightened Pediatric Caution

Tesamorelin is a 44-amino-acid synthetic analog of endogenous GHRH. It stimulates pituitary somatotroph cells to release growth hormone (GH), which in turn raises insulin-like growth factor 1 (IGF-1) [1]. In the adult trials reported by Falutz et al. (N=412), tesamorelin 2 mg daily produced a 15% reduction in trunk fat measured by CT scan at 26 weeks versus placebo [4]. IGF-1 levels rose by a mean of 81% from baseline in the treatment arm.

That 81% IGF-1 increase matters more in a child. Children under 12 have open growth plates, active linear growth, and a GH-IGF-1 axis that is already physiologically amplified compared to adults [5]. Supraphysiologic IGF-1 in a prepubertal child introduces risks that simply do not apply to a 45-year-old adult: accelerated bone age advancement, premature epiphyseal fusion, and theoretical concern about proliferative effects on developing tissues.

The Endocrine Society's 2011 clinical practice guideline on GH use in children emphasizes that any intervention stimulating the GH-IGF-1 axis in pediatric patients requires "serial monitoring of IGF-1, bone age, and growth velocity at minimum every 6 months" [6]. Tesamorelin is not GH itself, but it acts upstream on the same axis.

Baseline Assessments Before Any Off-Label Pediatric Use

If a pediatric endocrinologist and HIV specialist jointly determine that off-label tesamorelin is clinically warranted for a child under 12, baseline evaluation should be thorough. No published guideline covers this exact scenario. The following framework synthesizes adult tesamorelin labeling [2], Endocrine Society pediatric GH-axis monitoring standards [6], and the Infectious Diseases Society of America (IDSA) pediatric HIV management recommendations [7].

Anthropometric and growth baseline. Record standing height, weight, BMI-for-age percentile, and Tanner stage. Obtain a left-hand radiograph for bone age assessment using the Greulich-Pyle atlas. Document mid-parental height and prior growth velocity (cm/year over the preceding 12 months).

Endocrine labs. Draw fasting serum IGF-1 and IGFBP-3 with age- and sex-matched reference ranges. Obtain a full pituitary panel: TSH, free T4, morning cortisol, LH, FSH, and estradiol or testosterone. Prepubertal children with HIV may already have subtle hypothalamic-pituitary dysfunction from chronic inflammation or prior CNS opportunistic infections [8].

Metabolic labs. Fasting glucose, fasting insulin, and HbA1c are required. The adult tesamorelin trials showed a 0.1% mean increase in HbA1c versus placebo and a 3.6 mg/dL rise in fasting glucose [4]. In children, whose insulin sensitivity differs from adults, this effect could be amplified. A 2-hour oral glucose tolerance test (OGTT) should be considered if the child has additional diabetes risk factors.

Body composition imaging. Dual-energy X-ray absorptiometry (DXA) provides regional fat mass and lean mass data without the radiation dose of CT. For children, DXA is preferred over CT for serial monitoring [9].

Hepatic safety. Obtain ALT, AST, and GGT. The adult Egrifta label notes cases of injection-site reactions and hypersensitivity but does not flag hepatotoxicity. Pediatric HIV patients on ART, though, frequently carry background hepatic enzyme elevations from concomitant antiretrovirals [7].

IGF-1 Monitoring: The Central Biomarker

IGF-1 is the single most important lab value to track during tesamorelin therapy in any age group. The FDA label recommends measuring IGF-1 at baseline and during treatment in adults, discontinuing the drug if no visceral fat reduction occurs after 6 months [2].

In a child, the bar should be higher. The Endocrine Society defines IGF-1 above +2 SDS (standard deviation score) for age and sex as a threshold warranting dose reduction or discontinuation of GH-axis therapies [6]. Dr. Bradley S. Miller, pediatric endocrinologist at the University of Minnesota, has stated regarding GH-axis therapies in children: "IGF-1 levels persistently above +2 SDS should trigger dose adjustment regardless of the clinical indication, because long-term safety data above that threshold are insufficient in growing children" [10].

For a child receiving off-label tesamorelin, IGF-1 should be drawn at baseline, at 4 weeks after initiation, then every 3 months. Each result must be interpreted using pediatric-specific, Tanner-stage-matched reference ranges. Adult reference ranges are not applicable. The difference is not trivial: a "normal" IGF-1 of 350 ng/mL in an adult male could represent a +3 SDS value in a 7-year-old girl.

If IGF-1 exceeds +2 SDS on two consecutive measurements 4 weeks apart, the drug should be stopped or the dose reduced. No published dose-titration data exist for tesamorelin in children, which makes IGF-1 tracking the only pharmacodynamic guide available.

Growth Velocity and Bone Age Surveillance

Linear growth acceleration is an expected pharmacologic effect of any therapy that raises GH and IGF-1. In children receiving exogenous GH for GH deficiency, first-year growth velocity typically increases from 4 to 5 cm/year to 10 to 12 cm/year [6]. Tesamorelin's effect on growth velocity in children is unknown, but the mechanism predicts some degree of acceleration.

Growth velocity should be measured every 3 months using a calibrated stadiometer. A velocity exceeding the 95th percentile for age and sex, or an increase of more than 2 cm/year above the pre-treatment baseline, should prompt reassessment.

Bone age radiographs should be obtained at baseline and every 6 months. Advancement of bone age by more than 1 year relative to chronological age over 6 months suggests excessive GH-axis stimulation. The concern is not height gain per se. The concern is that accelerated bone maturation could compromise adult height by closing epiphyses prematurely. A study by Kamp et al. in the Journal of Clinical Endocrinology & Metabolism (N=121 children on GH therapy) found that bone age advancement exceeding 1.5 years per year of treatment was associated with a 3.2 cm reduction in predicted adult height [11].

Glucose and Metabolic Monitoring

GH opposes insulin action. This is well established. In the adult tesamorelin Phase III trials, 4.5% of tesamorelin-treated patients developed new-onset diabetes versus 1.3% on placebo [4]. That 3.2 percentage-point difference occurred in adults with HIV, many of whom were already insulin-resistant from protease inhibitor therapy.

Children with perinatally acquired HIV face compounding metabolic stressors. A study from the PHACS network (N=395) reported that 15.2% of HIV-infected youth aged 7 to 16 had impaired fasting glucose, compared with 5.1% of HIV-exposed uninfected controls [12]. Adding a GH secretagogue to this population requires careful glucose surveillance.

Monitoring protocol for glucose metabolism:

• Fasting glucose and HbA1c at baseline, then every 3 months
• Consider fasting insulin and HOMA-IR calculation at baseline and 6 months
• OGTT if fasting glucose exceeds 100 mg/dL or HbA1c rises above 5.7%
• Immediate discontinuation of tesamorelin if fasting glucose exceeds 126 mg/dL on repeat testing or HbA1c reaches 6.5%

The American Diabetes Association (ADA) 2024 Standards of Care note that "drug-induced hyperglycemia in children warrants the same diagnostic thresholds as type 2 diabetes, with removal of the offending agent as first-line management" [13].

Monitoring for Hypersensitivity and Injection-Site Reactions

The adult Egrifta trials reported injection-site reactions (erythema, pruritus, pain, swelling) in 24.5% of tesamorelin-treated patients versus 13.4% on placebo [2]. One case of anaphylaxis was documented. Tesamorelin is contraindicated in patients with known hypersensitivity to tesamorelin or mannitol (an excipient).

Children under 12 may be less able to articulate early symptoms of hypersensitivity. Caregivers should be trained to recognize urticaria, facial edema, dyspnea, and lightheadedness. First injections should be administered in a clinical setting with resuscitation equipment available. For subsequent home injections, an epinephrine auto-injector (weight-appropriate dosing: 0.15 mg for children 15 to 30 kg) should be prescribed as a precaution.

Hypothalamic-Pituitary Axis Monitoring

Chronic exogenous GHRH stimulation could theoretically downregulate pituitary somatotroph responsiveness over time, though the adult trials did not demonstrate significant tachyphylaxis over 52 weeks [4]. In a developing child, the theoretical concern extends to other pituitary axes given the anatomic proximity of somatotroph, thyrotroph, and gonadotroph cells.

Monitor TSH and free T4 every 6 months. Obtain morning cortisol annually or sooner if the child develops symptoms of adrenal insufficiency (fatigue, weight loss, hypotension). In prepubertal children, LH and FSH are expected to be low. Any rise suggesting early activation of the gonadal axis should prompt evaluation for central precocious puberty, particularly in children under age 8 (girls) or age 9 (boys) [14].

Duration of Therapy and Discontinuation Protocol

The adult Egrifta label recommends discontinuation if trunk fat does not decrease after 6 months [2]. In a child, the risk-benefit calculus should be reassessed even sooner. A reasonable off-label approach would be to evaluate response at 3 months with DXA and waist circumference. If visceral adipose tissue has not decreased by at least 5% from baseline, continuation is difficult to justify given the absence of pediatric safety data.

When stopping tesamorelin, the adult data show that visceral fat returns to baseline within 3 to 6 months of discontinuation [15]. There is no known rebound effect on the GH-IGF-1 axis, but IGF-1 should be re-checked at 4 weeks and 3 months after stopping to confirm return to baseline.

Growth velocity should be documented for 12 months post-discontinuation. A bone age radiograph at 6 months after the final dose provides a useful endpoint to assess whether any skeletal advancement stabilizes.

Ethical and Regulatory Considerations

Off-label drug use in children occupies a specific regulatory space. The American Academy of Pediatrics (AAP) has stated that off-label prescribing "is sometimes the best available therapeutic option for children" but should be supported by "some evidence of efficacy from pharmacokinetic studies, case series, or extrapolation from adult data with appropriate dose adjustment" [16]. For tesamorelin in children under 12, even case series are absent.

Institutional review board (IRB) oversight should be considered if use is being contemplated in a research context. Informed consent from the parent or guardian must explicitly state that the drug is not approved for children, that no pediatric dosing data exist, and that monitoring protocols are based entirely on expert extrapolation from adult data and general pediatric endocrinology principles.